JPRN-UMIN000020244Completed未知
The low-fluence Q-switched 1,064-nm neodymium:yttrium-aluminium-garnet laser for the treatment of pigmented lesion; Prospective, randomized, and split-face comparative study - The study of laser torning for the treatment of the pigmented lesion;
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Wakayama Medical University
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 70years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •they have the severe disease
Investigators
Similar Trials
Completed
Not Applicable
A randomized, double-blind, placebo-controlled design phase 2 clinical trial to comparatively evaluate the efficacy and safety of CP-COV03 in patients with mild or moderate COVID-19Codes for special purposesKCT0007307Hyundai Bioscience300
Active, not recruiting
Phase 1
A placebo-controlled, proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritisGiant cell arteritisEUCTR2013-002778-38-ITInstitut de Recherches Internationales Servier (IRIS)50
Active, not recruiting
Not Applicable
A placebo-controlled, proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritisGiant cell arteritisEUCTR2013-002778-38-EEInstitut de Recherches Internationales Servier (IRIS)50
Active, not recruiting
Not Applicable
A placebo-controlled, proof-of concept study of the efficacy of gevokizumab subcutaneously over 24 weeks in the treatment of patients with polymyositis , dermatomyositis or necrotizing autoimmune myophaty diseasePolymyositis / Dermatomyositis /necrotizing autoimmune myophatyMedDRA version: 17.1Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 17.1Level: PTClassification code 10036102Term: PolymyositisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-005772-34-HUInstitut de Recherches Internationales Servier (IRIS)40
Active, not recruiting
Not Applicable
A placebo-controlled, proof-of concept study of the efficacy of gevokizumab subcutaneously over 24 weeks in the treatment of patients with polymyositis, dermatomyositis or necrotizing autoimmune myopathy disease.Polymyositis / Dermatomyositis / necrotizing autoimmune myopathyMedDRA version: 17.1Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 17.1Level: PTClassification code 10036102Term: PolymyositisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-005772-34-SEInstitut de Recherches Internationales Servier (IRIS)40